# A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome

> **NCT05140811** · PHASE1,PHASE2 · UNKNOWN · sponsor: **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.** · enrollment: 126 (estimated)

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** IMM01
- **DRUG:** Azacitidine

## Key facts

- **NCT ID:** NCT05140811
- **Lead sponsor:** ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-01-05
- **Primary completion:** 2024-02-05
- **Final completion:** 2024-03-01
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2023-05-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05140811

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05140811, "A Study of IMM01 Combined With Azacitidine in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05140811. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*